Why Gilead Might Do 'Nothing In Oncology' As Key Drugs Topple
Gilead Sciences (GILD) "might end up doing nothing in oncology" if the right takeover deal doesn't present itself, Chief Executive John Milligan reportedly told an analyst Wednesday.
The third-largest biotech by market cap, Gilead has struggled with declining sales of hepatitis C drugs for several quarters. In the first quarter, Gilead hinted that it could be looking to buy an oncology player. But Gilead remained mum on a potential merger in the recent second quarter.
The third-largest biotech by market cap, Gilead has struggled with declining sales of hepatitis C drugs for several quarters. In the first quarter, Gilead hinted that it could be looking to buy an oncology player. But Gilead remained mum on a potential merger in the recent second quarter.